KR102824092B1 - Cftr 강화제로서의 피롤로피리미딘 - Google Patents

Cftr 강화제로서의 피롤로피리미딘 Download PDF

Info

Publication number
KR102824092B1
KR102824092B1 KR1020237033420A KR20237033420A KR102824092B1 KR 102824092 B1 KR102824092 B1 KR 102824092B1 KR 1020237033420 A KR1020237033420 A KR 1020237033420A KR 20237033420 A KR20237033420 A KR 20237033420A KR 102824092 B1 KR102824092 B1 KR 102824092B1
Authority
KR
South Korea
Prior art keywords
pyrimidin
pyrrolo
fluorophenyl
amine
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237033420A
Other languages
English (en)
Korean (ko)
Other versions
KR20230146104A (ko
Inventor
조셉 월터 스트로바흐
데이비드 크리스토퍼 림버그
존 폴 마시아스
아틀리 소라렌센
라지아 알드린 데니
크리스토프 월프갱 자프
다니엘 엘바움
로리 크림 가브린
이반 빅토로비치 에프레모브
Original Assignee
시스틱 파이브로시스 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시스틱 파이브로시스 파운데이션 filed Critical 시스틱 파이브로시스 파운데이션
Publication of KR20230146104A publication Critical patent/KR20230146104A/ko
Application granted granted Critical
Publication of KR102824092B1 publication Critical patent/KR102824092B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
KR1020237033420A 2016-11-18 2017-11-17 Cftr 강화제로서의 피롤로피리미딘 Active KR102824092B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662423919P 2016-11-18 2016-11-18
US62/423,919 2016-11-18
KR1020197017510A KR102585398B1 (ko) 2016-11-18 2017-11-17 Cftr 강화제로서의 피롤로피리미딘
PCT/US2017/062148 WO2018094137A1 (en) 2016-11-18 2017-11-17 Pyrrolopyrimidines as cftr potentiators

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197017510A Division KR102585398B1 (ko) 2016-11-18 2017-11-17 Cftr 강화제로서의 피롤로피리미딘

Publications (2)

Publication Number Publication Date
KR20230146104A KR20230146104A (ko) 2023-10-18
KR102824092B1 true KR102824092B1 (ko) 2025-06-25

Family

ID=62144793

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237033420A Active KR102824092B1 (ko) 2016-11-18 2017-11-17 Cftr 강화제로서의 피롤로피리미딘
KR1020197017510A Active KR102585398B1 (ko) 2016-11-18 2017-11-17 Cftr 강화제로서의 피롤로피리미딘

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197017510A Active KR102585398B1 (ko) 2016-11-18 2017-11-17 Cftr 강화제로서의 피롤로피리미딘

Country Status (22)

Country Link
US (5) US10301315B2 (enExample)
EP (2) EP4424311A3 (enExample)
JP (3) JP6978507B2 (enExample)
KR (2) KR102824092B1 (enExample)
CN (2) CN115850268B (enExample)
AU (2) AU2017362350B2 (enExample)
CA (1) CA3044050A1 (enExample)
CL (1) CL2019001334A1 (enExample)
CO (1) CO2019005993A2 (enExample)
CR (1) CR20190292A (enExample)
DO (1) DOP2019000126A (enExample)
EC (1) ECSP19043120A (enExample)
ES (1) ES2983686T3 (enExample)
IL (3) IL296279A (enExample)
MX (2) MX387203B (enExample)
PE (1) PE20200739A1 (enExample)
PH (1) PH12019501098A1 (enExample)
PL (1) PL3541390T3 (enExample)
RU (2) RU2021129721A (enExample)
SG (1) SG10202106949XA (enExample)
UA (1) UA125400C2 (enExample)
WO (1) WO2018094137A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508407A (ja) 2012-01-06 2015-03-19 アビデ セラピューティクス，インク． カルバメート化合物およびその製造および使用
RS60906B1 (sr) 2014-10-06 2020-11-30 Vertex Pharma Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu
AU2016379388A1 (en) * 2015-12-22 2018-07-12 Proteostasis Therapeutics, Inc. Methods of treating pulmonary diseases and disorders
HUE056716T2 (hu) 2016-09-30 2022-03-28 Vertex Pharma Cisztás firbrózis transzmembrán konduktancia regulátor modulátora, gyógyszerészeti készítmények, kezelési eljárások, és eljárások a modulátor elõállítására
WO2018094137A1 (en) * 2016-11-18 2018-05-24 Cystic Fibrosis Foundation Therapeutics Inc. Pyrrolopyrimidines as cftr potentiators
EP3812379A1 (en) 2016-12-09 2021-04-28 Vertex Pharmaceuticals Incorporated Crystalline form of a n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide for treating cystic fibrosis
RU2753056C2 (ru) 2016-12-16 2021-08-11 Систик Файбросис Фаундейшн Бициклические гетероарильные производные в качестве стимуляторов cftr
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
ES2912657T3 (es) 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
JP7245834B2 (ja) 2017-12-08 2023-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
LT3752510T (lt) 2018-02-15 2023-04-11 Vertex Pharmaceuticals Incorporated Makrocikliniai junginiai kaip cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinės kompozicijos, jų panaudojimas cistinės fibrozės gydymui ir jų gamybos būdas
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
UY38630A (es) 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
KR20220019015A (ko) * 2019-06-10 2022-02-15 노파르티스 아게 Cf, copd, 및 기관지확장증 치료를 위한 피리딘 및 피라진 유도체
JP2022541178A (ja) 2019-07-15 2022-09-22 ノバルティス アーゲー （ｓ）－３－アミノ－６－メトキシ－ｎ－（３，３，３－トリフルオロ－２－ヒドロキシ－２－メチルプロピル）－５－（トリフルオロメチル）ピコリンアミド製剤
WO2021030552A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
EP4013741B1 (en) 2019-08-14 2024-04-17 Vertex Pharmaceuticals Incorporated Process of making cftr modulators
CN111138439B (zh) * 2020-01-17 2021-06-25 厦门大学 氟代吡咯并嘧啶类化合物及其制备方法和应用
WO2021176049A1 (en) 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12
EP4199914A4 (en) 2020-08-20 2024-09-04 The Board of Trustees of the Leland Stanford Junior University METHODS OF TREATMENT OF RESPIRATORY DISEASES CHARACTERIZED BY HYPERSECRETION OF MUCUS
KR20230118123A (ko) 2020-12-10 2023-08-10 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 치료 방법
TW202425990A (zh) * 2022-11-02 2024-07-01 南韓商日東製藥股份有限公司 包含ｃｆｔｒ調節劑化合物之點眼用組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009062118A2 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2128544T3 (es) * 1992-12-17 1999-05-16 Pfizer Pirrolopirimidinas como antagonistas del crf.
NZ518726A (en) * 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
JP2004534779A (ja) * 2001-05-30 2004-11-18 エルジー ライフサイエンス リミテッド 疾病治療用プロテインキナーゼ阻害剤
US20050008640A1 (en) * 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
CA2553724A1 (en) * 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
TW201307354A (zh) * 2005-12-29 2013-02-16 Abbott Lab 蛋白質激酶抑制劑
ATE531718T1 (de) * 2006-03-11 2011-11-15 Vernalis R&D Ltd Als hsp90-inhibitoren verwendete pyrrolopyrimidinderivate
KR20090017498A (ko) * 2006-04-04 2009-02-18 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Ｐｉ３ 키나제 길항물질
CA2749228C (en) * 2009-01-08 2016-05-17 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
US20130123281A1 (en) 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules
US8828998B2 (en) * 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014060431A1 (en) * 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
WO2015091532A1 (en) * 2013-12-19 2015-06-25 Almirall, S.A. Pyrrolopyrimidine derivatives as pi3k inhibitors
WO2018094137A1 (en) * 2016-11-18 2018-05-24 Cystic Fibrosis Foundation Therapeutics Inc. Pyrrolopyrimidines as cftr potentiators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009062118A2 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking

Also Published As

Publication number Publication date
US20200017512A1 (en) 2020-01-16
CN110337294B (zh) 2022-11-01
MX2019005822A (es) 2019-09-09
CN110337294A (zh) 2019-10-15
EP4424311A2 (en) 2024-09-04
PL3541390T3 (pl) 2024-09-09
PE20200739A1 (es) 2020-07-24
WO2018094137A1 (en) 2018-05-24
IL266668A (en) 2019-07-31
KR20190110088A (ko) 2019-09-27
AU2022201816A1 (en) 2022-04-07
KR20230146104A (ko) 2023-10-18
EP3541390A1 (en) 2019-09-25
SG10202106949XA (en) 2021-07-29
EP3541390C0 (en) 2024-05-01
CN115850268A (zh) 2023-03-28
JP7360434B2 (ja) 2023-10-12
JP2022024023A (ja) 2022-02-08
US20180141954A1 (en) 2018-05-24
JP6978507B2 (ja) 2021-12-08
US20190225621A1 (en) 2019-07-25
UA125400C2 (uk) 2022-03-02
AU2022201816B2 (en) 2024-02-15
CA3044050A1 (en) 2018-05-24
CO2019005993A2 (es) 2019-07-31
US20210171534A1 (en) 2021-06-10
DOP2019000126A (es) 2019-08-30
IL314404B1 (en) 2025-09-01
US10301315B2 (en) 2019-05-28
CN115850268B (zh) 2025-06-27
BR112019010167A2 (pt) 2019-09-17
JP7592814B2 (ja) 2024-12-02
MX2021012639A (es) 2022-10-03
IL314404A (en) 2024-09-01
IL266668B (en) 2022-10-01
JP2020510668A (ja) 2020-04-09
KR102585398B1 (ko) 2023-10-10
MX387203B (es) 2025-03-18
US20230250100A1 (en) 2023-08-10
AU2022201816A8 (en) 2022-04-21
CL2019001334A1 (es) 2019-11-15
ECSP19043120A (es) 2019-08-30
PH12019501098A1 (en) 2019-09-09
RU2019118623A3 (enExample) 2021-03-18
RU2757457C2 (ru) 2021-10-18
IL266668B2 (en) 2023-02-01
EP3541390B1 (en) 2024-05-01
JP2023182694A (ja) 2023-12-26
US10494374B2 (en) 2019-12-03
EP3541390A4 (en) 2020-06-24
ES2983686T3 (es) 2024-10-24
RU2021129721A (ru) 2021-11-26
AU2017362350A1 (en) 2019-06-20
AU2017362350B2 (en) 2021-12-23
EP4424311A3 (en) 2024-12-18
CR20190292A (es) 2019-09-03
NZ754085A (en) 2025-05-02
IL296279A (en) 2022-11-01
RU2019118623A (ru) 2020-12-21

Similar Documents

Publication Publication Date Title
KR102824092B1 (ko) Cftr 강화제로서의 피롤로피리미딘
AU2021277702B2 (en) Bicyclic heteroaryl derivatives as CFTR potentiators
HK40014108A (en) Pyrrolopyrimidines as cftr potentiators
HK40014108B (en) Pyrrolopyrimidines as cftr potentiators
BR122022008825B1 (pt) Compostos pirrolopirimidinas potenciadores de cftr, composição farmacêutica que compreende os mesmos e usos terapêuticos dos ditos compostos e composição
BR112019010167B1 (pt) Compostos pirrolopirimidinas potenciadores de cftr
HK40015891B (en) Bycyclic heteroaryl derivatives as cftr potentiators
HK40015891A (en) Bycyclic heteroaryl derivatives as cftr potentiators

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230926

Application number text: 1020197017510

Filing date: 20190618

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240726

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250321

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250618

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250619

End annual number: 3

Start annual number: 1

PG1601 Publication of registration